Update rheumatology - Part II;Update rheumatologie - Teil II. Stand und perspektiven der pharmakotherapie chronischer arthritiden

Medizinische Klinik

Volumn 94, Issue 10, 1999, Pages 556-563

  Hein, Gert ^a   Eidner, Thorsten ^b   Oelzner, Peter ^b   Manger, Bernhard ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BREQUINAR; COLECALCIFEROL; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; ETANERCEPT; ETIDRONIC ACID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MISOPROSTOL; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PENICILLAMINE; RAPAMYCIN; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHRONIC DISEASE; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; OSTEOPOROSIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; VITAMIN D DEFICIENCY;

EID: 0033569598     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03044953     Document Type: Review

References (96)

1. Blum AL, Bolten WW, Labenz J. et al. Therapie und Prävention des ASS- und NSAR-Ulkus. Dtsch Ärztebl 1998;95:348-54.
2. Brune K, Hinz B. Selektive Cyclooxygenase-2-Hemmer: Glaube, Hoffnung, Realität. Aktuel Rheumatol 1998;23:1-5.
3. Brune K, Hinz B.: Zum aktuellen Stand der Zyklooxygenaseforschung. Dtsch Ärztebl 1998;95:343-6.
4. Brune K, Glatt M, Graf P. Mechanism of action of inflammatory drugs. Gen Pharmacol 1976;7:27-33.
5. Frölich JC. Pharmakologische Wirkungen von antiphlogistischen Substanzen auf den Knorpel. Z Rheumatol 1998;57:185.
6. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-40.
7. Geis GS, Stead H, Morand S, et al. Efficacy and safety of celecoxib, a specific Cox-2 inhibitor in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:Suppl:1699.abstract.
8. Gonzales E, de la Cruz C, de Nicola's R. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agent Action 1994;41:171-8.
9. Herschman HR. Prostaglandin-Synthase 2. Biochim Biophys Acta 1996;1299:125-40.
10. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with Misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.
11. Hubbard RC, Koepp RJ, Yu S, et al. SC-58635 (Celecoxib). a novel Cox-2 selctive inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum 1996;39:Suppl:1188.abstract.
12. Martel-Pelletier J, Cloutier J-M, Pelletier J-P. Effects of aceclofenac and Ddiclofenac on synovial inflammatory factor in human osteoarthritis. Clin Drug Invest 1997;14:226-32.
13. Sano H, Hashiramoto A, Yamada R, et al. Treatment of rheumatoid arthritis and rat adjuvant-induced arthritis by cyclooxygenase-2 antisense through induction of apoptosis. Arthritis Rheum 1998;41:Suppl:772.abstract.
14. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum 1998;41:1591-602.
15. Stichenroth D, Zeidler H, Frölich J. Neue nichtsteroidale Antirheumatika: Selektive Hemmstoffe der induzierbaren Cyclooxygenase. Med Klin 1998;93:407-15.
16. Tugwell P, Ortiz Z, Griffith B. Rheumatoid arthritis: Emerging evidence for the benefits of early and aggressive therapy. Dis Managem Hlth Outcomes 1997;3:141-53.
17. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 1971;231 () 232-5.
18. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with Rranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719-26.
19. American College of Rheumatology Task Force on Osteoporosis Guidelines: Recommendations of the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;1791-01.
20. Arvidson NG, Gudbjornsson B, Larsson A, et al. The timing of glucocorticoid administration in the rheumatoid arthritis. Ann Rheum Dis 1997;56:27-31.
21. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids. Inhibition of NF-kB activity through induction of IkBa synthesis. Science 1995;270:286-90.
22. Bamberger CM, Schulte HM. Wirkungsmechanismus der Glucocorticoide. Internist (Berlin) 1997;38:366-70.
23. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200-57.
24. Boumpas DT, Pahogianni F, Anastassiou ED, et al. Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol 1991; 9:413-23.
25. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-8.
26. Civitelli R. The role of vitamin D metabolites in the treatment of osteoporosis. Calcif Tissue Int 1995;57:409-14.
27. Cortet B, Flipo RM, Blanckaert F, et al. Evalution of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum Engl Ed 1997;64:451-8.
28. Crofford LJ, Kalogeras KT, Mastorakos G, et al. Circadian relationship between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones. Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279-83.
29. Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996;35:309-22.
30. Dequeker J, Maenaut K, Verwilghen J, et al. Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 1995;13:Suppl 12:S21-6.
31. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996;39:396-402.
32. Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7.
33. Goulding NJ, Godolphin JL, Sharland PR, et al. Anti-inflammatory lipocortin 1 is produced by peripheral blood leucocytes in response to intravenous hydrocortisone. Lancet 1990;335:1416-9.
34. Goulding NJ. Corticosteroids - a case ot mistaken identity? Br J Rheumatol 1998;37:477-80.
35. Gudbjornsson B, Skogseid B, Oberg K, et al. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. J Rheumatol 1996;23:596-602.
36. Joyce DA, Steer JH, Abraham LJ. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-a secretion. Inflamm Res 1997;46:447-51.
37. Kirwan JR. ARC Low-dose Glucocorticoid Study Group. The effect of glucocorticoid and joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
38. Kirwan JR, Kim KK. Low dose corticosteroids in early rheumatoid arthritis: Can these drugs slow disease progression? Drugs Aging 1996;8:157-61.
39. Masi AT, Chrousos GP. Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis 1997;56:1-4.
40. McGill PE, Kerr H, Stirling A. Effect of cyclical etidronate on BMD in steroid treated RA. Bone 1997;20:Suppl:S99.
41. Oelzner P, Müller A, Deschner F, et al. Relationship between disease activity and serum levels ol vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998;62:193-8.
42. Oelzner P, Hein G. Entzündung und Knochenstoffwechsel bei rheumatoider Arthritis - Pathogenetische Gesichtspunkte und therapeutische Möglichkeiten. Med Klin 1997;92:607-14.
43. Peel NF,Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
44. Ringe JD. Generalisierte Osteoporose bei chronischer Polyarthritis - Pathomechanismen und Behandlungsansätze. Z Rheumatol 1996;55:149-57.
45. Saag KG, Criswell LA, Sems KM, et al. Low dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996;39:1818-25.
46. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993; 328: 1747-52.
47. Sambrook PN, Jones J. Corticosteroid osteoporosis. Br J Rheumatol 1995;34:8-12.
48. Scheinman RI, PC Cogswell, Lofquist AK, et al. Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 1995;270: 283-6.
49. Stichtenoth DO, Frolich JC. Nitric oxide and inflammatory joint diseases. Br J Rheumatol 1998;37:246-57.
50. Tarbadel Y, Duchateau J, Schmartz D, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996;119:76-80.
51. Verstraeten A, Dequeker J, Nijs J, et al. Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two year prospective study. Clin Exp Rheumatol 1989;7:351-8.
52. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
53. Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1996;35:1142-9.
54. Burkhardt H, Kalden J. Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatol Int 1997;17:85-90.
55. Chaudhuri K, Torley H, Madhok R, Cyclosporin. Br J Rheumatol 1997;36:1016-21.
56. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive ar. thritis (Reiter's syndrome). Arthritis Rheum 1996; 39:2021-7.
57. Clegg DO, Reda DJ, Weisman MH, et al.: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996;39:2004-12.
58. Egsmose C, Hansen TM, Andersen LS, et al. Limitid effect of sulfasalzine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis 1997;56:32-6.
59. Flipo RM, Emery P, Scott DG, et al. Safety and tolerability of conversion from stable Sandimmun maintenance treatment to Sandimmun Neoral in patients with rheumatoid arthritis. J Rheumatol 1998;25:1263-9.
60. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998;53:Suppl:20-6.
61. Jones G, Crotty M, Brooks P, The Psoriatic Arthritis Meta-Analysis Study Group. Psoriatic arthritis: A quantitative overview of therapeutic options. Br J Rheumatol 1997;36:95-9.
62. Li E, Brooks P, Conaghan PC. Disease-modifying anti-rheumatic drugs. Curr Opin Rheumatol 1998; 10:159-68.
63. Lorenz HM, Geiler T, Kalden JR. Immunosuppressive Therapiemodalitäten bei chronischen Polyarthritiden. Internist (Berlin) 1997;38:532-40.
64. Moreland LW, Fleischmann RM, for the Leflunomide RA Investigators Group and Strand V. Efficacy of leflunomide vs placebo vs methotrexate in early and late rheumatoid arthritis. Arthritis Rheum 1998;41:Suppl:S155.
65. Olivieri I, Salvarani C, Cantini E, et al. Therapy with cyclosporin in psoriatic arthritis. Semin Arthritis Rheum 1997;27:36-43.
66. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006-15.
67. Rau R, Furst DE, Menninger H, et al. Kombinationstherapie bei chronischer Polyarthritis. Z Rheumatol 1998;57:17-49.
68. Rozmann B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators Group. J Rheumatol 1998;53:Suppl:27-32
69. Schnülle P, van der Woude FJ. Mycophenolat Mofetil im Vergleich zu anderen Immunosuppressiva. Internist (Berlin) 1998;39:879-86.
70. Smolen JS, Kalden JR, Scott DL, et al., the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalzine in active rheumatoid arthritis: a double-blind. randomised, multicentre trial. Lancet 1999;353:259-66.
71. Somerville MF, Scott DG. Neoral - new cyclosporin for old? Br J Rheumatol 1997;36:1113-5.
72. Stein CM, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: and open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 1997;40:1843-51.
73. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
74. van den Borne BE, Landewe RB, Goei The HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998;25:1493-8.
75. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998;37:612-9.
76. Zeidler HK, Kvien TK, Hannonen P, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: Comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998; 37:874-82.
77. Zink A, Listing J, Gu F, et al., Modellverbund BMG-geförderter Rheumazentren. Rheumatologische Kerndokumentation in den BMG-geförderten Rheumazentren im Jahr 1995. Deutsches Rheuma-Forschungszentrum Berlin. Forschungsbereich Epidemiologic. Epi-Report No 6, Berlin, Juli 1997.
78. Alsalameh S, Kalden JR, Burmester GR. Die Rolle von Zytokinen und Wachstumsfaktoren bei der rheumatoiden Gelenkdestruktion. Z Rheumatol 1991;50:347-59.
79. Bresinhan B, on behalf of the collaborating investigators. Lookabaugh J, Witt K, Mukisic P. Treatment with recombinant human interleukin-1 receptor antagonist (rhuIL-Ira) in rheumatoid arthritis: Results of a randomized double-blind, placebo-controlled multicenter study. Arthritis Rheum 1996;39:Suppl 9:73.
80. Burmester GR, Manger B, Kalden J. Immunopathogenese entzündlich-rheumatischer Erkrankungen. Dtsch Ärztebl 1995;92:1010-20.
81. Chu CQ, Field M, Feldmann M, et al. Localization of tumour necrosis factor a in synovial tissues and at UV cartilage pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
82. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor a. Arthritis Rheum 1993;36:1681-90.
83. Elliot MJ, Maini RN, Feldmann VI, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
84. Kalden JR, Manger B. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1996;8:195-200.
85. Kalden-Nemeth D, Grebmeier J, Antoni C, et al. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol Int 1997;16:249-55.
86. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by i. v. infusion of a chimeric, monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996;156:1646-53.
87. Maini RN. Monoclonal anti-TNFa antibody (cA2) in the treatment of rheumatoid arthritis. In: Feng PH, ed. Proc of the XIXth ILAR Congress of Rheumatology. Singapore: Communication Consultants, 1997:459-64.
88. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
89. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
90. Rankin EC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
91. Salfeld J, Kaymakçalan Z, Tracey D, et al. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum 1998;41:S57.
92. Schattenkirchner M, Kruger K, Sander O, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis - results of a phase 1 study. Arthritis Rheum 1998;41:S57.
93. van de Putte L, van Riel P, den Broeder A, et al. A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:S57.
94. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein. in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
95. Weinblatt ME, Moreland LW, Schiff MH, et al. Longterm and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75-Fc-fusion protein (TNF:Fc:ENBRELTM). Arthritis Rheum 1997;40:S59.
96. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993;14:243-6.